Intensified Therapy Shows Promise for Lupus Nephritis
A new trial finds intensified B-cell depletion therapy can reduce steroid use and help patients avoid maintenance medication.
Updated on Oct. 21, 2026 in Stroke
Live Poll
Should doctors prioritize shorter, steroid-sparing treatments over long-term medication regimens for chronic conditions?
The INTONATE trial shows that an intensified B-cell depletion therapy regimen leads to better renal response and lower glucocorticoid exposure in lupus nephritis patients compared to standard care. Researchers followed 54 participants over 30 months to evaluate the efficacy of the treatment protocol.
Why it matters
Patients with lupus nephritis often require long-term treatment with high doses of glucocorticoids and immunosuppressants, which carry significant side effects. This study demonstrates a pathway to achieving remission while minimizing the need for ongoing maintenance drugs.
The INTONATE trial, a multicenter study of 54 participants, found that patients receiving intensified B-cell depletion therapy achieved a 70% renal response rate at 30 months, compared to 59% for those on standard therapy.
The players
INTONATE trial
This is a multicenter open-label randomized controlled trial designed to analyze the effectiveness of various treatments for lupus nephritis.
The details
The randomized 1:1 study compared the new therapy against a regimen of mycophenolate mofetil and glucocorticoids. Patients in the intensified B-cell depletion group maintained a median cumulative glucocorticoid dose of 1.42 grams, less than half the 3.05 grams required by the standard therapy group.
Timeline
Participants were evaluated for total renal response at 12 months.
Researchers assessed sustained remission and renal flares over a period of 30 months.
The Big Picture
The findings from the INTONATE randomized controlled trial represent a shift in managing lupus nephritis by prioritizing B-cell depletion to lower patient reliance on traditional steroids. This follows a broader medical trend of moving toward targeted immunotherapies to achieve durable remission.
For patients with lupus nephritis, this therapy offers the potential for reduced reliance on maintenance immunosuppressants and lower overall steroid exposure. These findings may eventually alter standard treatment routines and improve long-term quality of life by mitigating common medication side effects.
The takeaway
This study highlights that targeted B-cell depletion may allow some patients to achieve remission without the burden of ongoing maintenance immunosuppression. Patients should consult with their rheumatologists to discuss how these emerging protocols might eventually influence their personalized treatment plans.
Further reading
Learn more about the latest research in this field by visiting the Stroke section.
Source note: This article includes information reported by Derm Immuno Today.
Live Poll
Should doctors prioritize shorter, steroid-sparing treatments over long-term medication regimens for chronic conditions?
